A Sacrococcygeal Teratoma (SCT) is a rare medical miracle that occurs in newborn babies, usually in the first month of life. It is an abnormal growth that develops in the area of the baby’s tailbone. It is most often benign, meaning it is non-cancerous, but can also be malignant, or cancerous. In either case, it is a medical emergency that requires immediate attention. SCTs are classified as either type 1 or type 2. Type 1 SCTs are typically benign and occur in the lower portion of the tailbone. Type 2 SCTs are more likely to be malignant and occur higher up in the tailbone. Both types can cause serious health problems for the baby, including breathing difficulties, developmental delays, and even death.
The exact cause of SCT is unknown, but it is believed to be related to genetic factors. It is also thought that environmental factors, such as exposure to certain chemicals or radiation, may play a role.
SCTs are diagnosed through a physical exam and imaging tests such as ultrasound or magnetic resonance imaging (MRI). Treatment depends on the size and type of the tumor, as well as the age and overall health of the baby. For type 1 SCTs, the tumor is usually surgically removed. In some cases, chemotherapy or radiation may be used to shrink the tumor before surgery. For type 2 SCTs, the tumor may be treated with chemotherapy or radiation, or the entire tumor may be surgically removed.
The outlook for babies with SCTs is generally good. With prompt diagnosis and treatment, most babies make a full recovery. However, there is a risk of complications, including infection, bleeding, and organ damage. In some cases, the tumor may recur or spread to other parts of the body.
A Sacrococcygeal Teratoma is a rare medical miracle that can occur in newborn babies. It is classified as either type 1 or type 2, with type 1 being the more common and benign form. Diagnosis and treatment depend on the size and type of the tumor, as well as the age and overall health of the baby. With prompt diagnosis and treatment, most babies make a full recovery, although there is a risk of complications.
1.
In Acute Myeloid Leukemia Diagnosed Recently, FLT3 Inhibitor Is Very Effective.
2.
Increased Data Support Active Monitoring for Low-Risk Prostate Cancer.
3.
Temsirolimus Plus Chemotherapy Fails in Rare Childhood Cancer
4.
A prostate cancer risk prediction algorithm could help target men at highest risk
5.
A smartphone app enhances the tracking of recovery following breast and gynecologic oncology surgery, according to JAMA.
1.
KEYNOTE-826: Optimizing Outcomes in Persistent, Recurrent, or Metastatic Cervical Cancer
2.
Bone Marrow Regeneration in Hematologic Recovery
3.
Esophageal Cancer Survival Rates and Outcomes: Evidence-Based Insights from Oncology Studies
4.
Iron Homeostasis Throughout the Female Lifespan
5.
Demystifying Lymphocytes: Everything You Need to Know
1.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
2.
International Cancer Conference
3.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
4.
Asian Symposium on Advancement in Hematology and Oncology
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
Untangling The Best Treatment Approaches For ALK Positive Lung Cancer - Part VIII
2.
Current Scenario of Blood Cancer- Further Discussion on Genomic Testing & Advancement in Diagnosis and Treatment
3.
Efficient Management of First line ALK-rearranged NSCLC - Part VIII
4.
Revolutionizing Treatment of ALK Rearranged NSCLC with Lorlatinib - Part V
5.
Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update) - Part III
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation